H. Alnajashi, “Rituximab as an off Label, High Efficacy Therapy in The Treatment of Multiple Sclerosis and Related Central Nervous System Demyelinating Diseases: Single Centre Experience and Literature Review”, J. Contemp. Med. Sci., vol. 11, no. 3, Jun. 2025.